| EMA number | EMEA/H/C/002800 |
| ATC code | L01FX06 |
| Authorisation | 14 August 2015 |
| Withdrawn | 20 March 2017 |
| Revision | 3 |
Unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.